Summary: Inflammatory bowel diseases (IBD), including Crohnʼs disease and ulcerative colitis, are chronic systemic disorders associated with an increased risk of cardiovascular complications. Chronic inflammation plays a central role in their pathogenesis, significantly affecting lipid metabolism and leading to characteristic disturbances referred to as the “lipid paradox.” Despite reduced levels of total cholesterol as well as LDL and HDL fractions, patients with IBD exhibit an elevated risk of atherosclerosis and cardiovascular events. These mechanisms involve lipoprotein dysfunction, qualitative changes in LDL particles, and loss of the anti-inflammatory properties of HDL. Beyond their well-established lipid-lowering effects, statins exhibit anti-inflammatory, immunomodulatory, and potentially anticancer properties. Observational studies suggest that statin use is associated with a reduced risk of incident IBD and a milder disease course, including fewer hospitalizations and surgical interventions. Additionally, statins may lower the risk of cardiovascular events and colorectal cancer in this population. However, current evidence is largely based on observational data and remains inconclusive. Further randomized controlled trials are required to clarify the optimal role of statins in IBD management and to determine their long-term impact on patient outcomes.